The Federal Court has given the greenlight to a $30 million settlement in Shine Lawyers’ insurance class action against Westpac and will allow post-settlement registration notices to be sent to group members.
The former senior counsel in a settled insurance class action against Westpac has had his fees reduced by $70,000 after the Federal Court heard some of the work for which he charged was not done in the interests of group members.
The applicant in a shareholder class action against IOOF wants to add ten new misconduct allegations, including that a relative of a former executive made $69,000 by offloading shares.
SkyCity’s announcement to shareholders about an employee’s interrogation by Chinese gambling authorities made little difference to the NZ casino operator’s share price, Crown Resorts has told a court in expert evidence ahead of a looming class action trial.
The judge overseeing class actions against Commonwealth Bank over its money laundering compliance failures has threatened to force the parties to go to trial by a certain date if they can’t agree to “sensible” time limits to ready the case for hearing, noting he would reach retirement age in 2024.
A judge has slammed an “absurd” class action settlement offer made by pelvic mesh device maker Astora Women’s Health that would require Shine Lawyers to provide the company with indemnities, saying “no rational judge” would approve it.
A solicitor who admitted to allegations of professional misconduct has lost a NSW Court of Appeal bid for the costs of a NCAT proceeding to be paid from the state’s Public Purpose Fund, despite twice winning appeals of the tribunal’s findings.
A judge has dismissed jailed property developer Salim Mehajer’s defamation lawsuit against broadcaster Seven, saying delays in fixing significant defects in his case amounted to an abuse of process.
Sydney’s ongoing COVID-19 lockdown has created “logistical” difficulties delaying the release of a long awaited judgment in the ACCC’s consumer law case against collapsed private college Phoenix Institute, which was accused of misleading students through the marketing of its courses.
Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival’s claims.